Supported Entera Bio's oversubscribed $275M PIPE financing to fund its Phase 3 program for EB613.
Entera is a leader in the development of orally delivered macromolecules, including peptides and other therapeutic proteins
Entera is a leader in the development of orally delivered macromolecules, including peptides and other therapeutic proteins. The Company focuses on significant unmet medical needs where a mini daily tablet form of a peptide treatment or replacement therapy holds the potential to transform the standard of care.